Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: January 28, 2022

DrugPatentWatch Database Preview

Details for Patent: 8,158,645

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,158,645 protect, and when does it expire?

Patent 8,158,645 protects HYCAMTIN and is included in one NDA.

This patent has eighteen patent family members in sixteen countries.

Summary for Patent: 8,158,645

Title:	Compound, corresponding compositions, preparation and/or treatment methods
Abstract:	Disclosed is a novel crystalline form of topotecan monohydrochloride pentahydrate, which is a pentahydrate of 10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indo- lizino[1,2-b]quinoline-3,14(4H,12H)dione monohydrochloride, corresponding pharmaceutical compositions, methods preparation and/or use thereof to treat anti-viral and/or cancer-related diseases.
Inventor(s):	Dell'Orco; Philip C. (King of Prussia, PA), Diederich; Ann Marie (King of Prussia, PA), Su; Qiaogong (King of Prussia, PA), Wood; Jeffery Lee (King of Prussia, PA)
Assignee:	GlaxoSmithKline LLC (Philadelphia, PA)
Application Number:	12/770,898
Patent Claim Types: see list of patent claims	Composition; Compound; Process; Formulation;

Drugs Protected by US Patent 8,158,645

Subscribe to access the full database, or Sign up for a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-001	Oct 11, 2007		RX	Yes	No	⤷ Sign up for a Free Trial	⤷ Sign up for a Free Trial	Y				⤷ Sign up for a Free Trial
Novartis	HYCAMTIN	topotecan hydrochloride	CAPSULE;ORAL	020981-002	Oct 11, 2007		RX	Yes	Yes	⤷ Sign up for a Free Trial	⤷ Sign up for a Free Trial	Y				⤷ Sign up for a Free Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,158,645

Subscribe to access the full database, or Sign up for a Free Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	046579	⤷ Sign up for a Free Trial
Australia	2004289318	⤷ Sign up for a Free Trial
Brazil	PI0416366	⤷ Sign up for a Free Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter

Harvard Business School

Boehringer Ingelheim

Merck

Moodys

AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.